nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—Carboplatin—testicular cancer	0.329	0.539	CbGbCtD
Octreotide—MPO—Cisplatin—testicular cancer	0.281	0.461	CbGbCtD
Octreotide—SSTR4—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00716	0.08	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00542	0.0606	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.0052	0.0581	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.0048	0.0536	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00461	0.0515	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—INSL3—testicular cancer	0.00426	0.0476	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—INSL3—testicular cancer	0.00365	0.0408	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00364	0.0406	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00349	0.039	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00309	0.0346	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00285	0.0319	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—INSL3—testicular cancer	0.00277	0.031	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—INSL3—testicular cancer	0.00266	0.0297	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00251	0.0281	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—INSL3—testicular cancer	0.00236	0.0263	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—INSL3—testicular cancer	0.00217	0.0243	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—INSL3—testicular cancer	0.00207	0.0231	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—INSL3—testicular cancer	0.00188	0.021	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00175	0.0196	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—KITLG—testicular cancer	0.00161	0.018	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—INSL3—testicular cancer	0.00157	0.0175	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—INSL3—testicular cancer	0.0015	0.0168	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—INSL3—testicular cancer	0.00142	0.0159	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—INSL3—testicular cancer	0.00136	0.0152	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—INSL3—testicular cancer	0.00133	0.0149	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—INSL3—testicular cancer	0.00123	0.0137	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—INSL3—testicular cancer	0.00121	0.0135	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—INSL3—testicular cancer	0.00112	0.0125	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—INSL3—testicular cancer	0.00111	0.0124	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—KIT—testicular cancer	0.0011	0.0123	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—INSL3—testicular cancer	0.00084	0.00938	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—INSL3—testicular cancer	0.000805	0.009	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—INSL3—testicular cancer	0.000714	0.00798	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—INSL3—testicular cancer	0.000659	0.00736	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—H2AFZ—testicular cancer	0.000355	0.00396	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—STK11—testicular cancer	0.000353	0.00394	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KITLG—testicular cancer	0.000326	0.00365	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—H2AFZ—testicular cancer	0.000269	0.003	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—STK11—testicular cancer	0.000267	0.00299	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—H2AFZ—testicular cancer	0.000258	0.00288	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—STK11—testicular cancer	0.000256	0.00286	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KITLG—testicular cancer	0.000247	0.00276	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—FGFR3—testicular cancer	0.000242	0.00271	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KITLG—testicular cancer	0.000237	0.00265	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—H2AFZ—testicular cancer	0.000229	0.00255	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—STK11—testicular cancer	0.000227	0.00254	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KIT—testicular cancer	0.000223	0.00249	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—H2AFZ—testicular cancer	0.000211	0.00236	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KITLG—testicular cancer	0.00021	0.00235	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—STK11—testicular cancer	0.00021	0.00234	CbGpPWpGaD
Octreotide—Dizziness—Ifosfamide—testicular cancer	0.000195	0.000651	CcSEcCtD
Octreotide—Pharyngitis—Methotrexate—testicular cancer	0.000195	0.00065	CcSEcCtD
Octreotide—Hepatobiliary disease—Epirubicin—testicular cancer	0.000194	0.000646	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—KITLG—testicular cancer	0.000194	0.00217	CbGpPWpGaD
Octreotide—Weight increased—Doxorubicin—testicular cancer	0.000194	0.000645	CcSEcCtD
Octreotide—Epistaxis—Epirubicin—testicular cancer	0.000194	0.000644	CcSEcCtD
Octreotide—Weight decreased—Doxorubicin—testicular cancer	0.000193	0.000641	CcSEcCtD
Octreotide—Sinusitis—Epirubicin—testicular cancer	0.000192	0.000641	CcSEcCtD
Octreotide—Feeling abnormal—Etoposide—testicular cancer	0.000192	0.00064	CcSEcCtD
Octreotide—Hyperglycaemia—Doxorubicin—testicular cancer	0.000192	0.000639	CcSEcCtD
Octreotide—Nausea—Dactinomycin—testicular cancer	0.000192	0.000638	CcSEcCtD
Octreotide—Pneumonia—Doxorubicin—testicular cancer	0.000191	0.000636	CcSEcCtD
Octreotide—Gastrointestinal pain—Etoposide—testicular cancer	0.000191	0.000635	CcSEcCtD
Octreotide—Drowsiness—Doxorubicin—testicular cancer	0.00019	0.000632	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—testicular cancer	0.00019	0.000631	CcSEcCtD
Octreotide—Vomiting—Ifosfamide—testicular cancer	0.000188	0.000626	CcSEcCtD
Octreotide—Hypersensitivity—Cisplatin—testicular cancer	0.000188	0.000625	CcSEcCtD
Octreotide—Bradycardia—Epirubicin—testicular cancer	0.000187	0.000624	CcSEcCtD
Octreotide—Rash—Ifosfamide—testicular cancer	0.000186	0.00062	CcSEcCtD
Octreotide—Dermatitis—Ifosfamide—testicular cancer	0.000186	0.00062	CcSEcCtD
Octreotide—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000186	0.000619	CcSEcCtD
Octreotide—Urticaria—Etoposide—testicular cancer	0.000185	0.000617	CcSEcCtD
Octreotide—Jaundice—Doxorubicin—testicular cancer	0.000185	0.000616	CcSEcCtD
Octreotide—Rhinitis—Epirubicin—testicular cancer	0.000185	0.000615	CcSEcCtD
Octreotide—Body temperature increased—Etoposide—testicular cancer	0.000185	0.000614	CcSEcCtD
Octreotide—Abdominal pain—Etoposide—testicular cancer	0.000185	0.000614	CcSEcCtD
Octreotide—Conjunctivitis—Doxorubicin—testicular cancer	0.000185	0.000614	CcSEcCtD
Octreotide—Urinary tract infection—Doxorubicin—testicular cancer	0.000185	0.000614	CcSEcCtD
Octreotide—Hepatitis—Epirubicin—testicular cancer	0.000184	0.000613	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—FGFR3—testicular cancer	0.000184	0.00205	CbGpPWpGaD
Octreotide—Tinnitus—Methotrexate—testicular cancer	0.000183	0.000611	CcSEcCtD
Octreotide—Hypoaesthesia—Epirubicin—testicular cancer	0.000183	0.00061	CcSEcCtD
Octreotide—Asthenia—Cisplatin—testicular cancer	0.000183	0.000609	CcSEcCtD
Octreotide—Pharyngitis—Epirubicin—testicular cancer	0.000183	0.000609	CcSEcCtD
Octreotide—Cardiac disorder—Methotrexate—testicular cancer	0.000183	0.000608	CcSEcCtD
Octreotide—Oedema peripheral—Epirubicin—testicular cancer	0.000181	0.000604	CcSEcCtD
Octreotide—Haematuria—Doxorubicin—testicular cancer	0.000181	0.000603	CcSEcCtD
Octreotide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00018	0.000598	CcSEcCtD
Octreotide—Epistaxis—Doxorubicin—testicular cancer	0.000179	0.000596	CcSEcCtD
Octreotide—Sinusitis—Doxorubicin—testicular cancer	0.000178	0.000593	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—testicular cancer	0.000178	0.000592	CcSEcCtD
Octreotide—Visual impairment—Epirubicin—testicular cancer	0.000177	0.000591	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FGFR3—testicular cancer	0.000176	0.00197	CbGpPWpGaD
Octreotide—Nausea—Ifosfamide—testicular cancer	0.000176	0.000584	CcSEcCtD
Octreotide—Diarrhoea—Cisplatin—testicular cancer	0.000174	0.00058	CcSEcCtD
Octreotide—Alopecia—Methotrexate—testicular cancer	0.000174	0.000579	CcSEcCtD
Octreotide—Bradycardia—Doxorubicin—testicular cancer	0.000173	0.000578	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—testicular cancer	0.000172	0.000574	CcSEcCtD
Octreotide—Hypersensitivity—Etoposide—testicular cancer	0.000172	0.000573	CcSEcCtD
Octreotide—Tinnitus—Epirubicin—testicular cancer	0.000172	0.000572	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—testicular cancer	0.000171	0.00057	CcSEcCtD
Octreotide—Erythema—Methotrexate—testicular cancer	0.000171	0.00057	CcSEcCtD
Octreotide—Flushing—Epirubicin—testicular cancer	0.000171	0.000569	CcSEcCtD
Octreotide—Cardiac disorder—Epirubicin—testicular cancer	0.000171	0.000569	CcSEcCtD
Octreotide—Rhinitis—Doxorubicin—testicular cancer	0.000171	0.000569	CcSEcCtD
Octreotide—Hepatitis—Doxorubicin—testicular cancer	0.00017	0.000567	CcSEcCtD
Octreotide—Hypoaesthesia—Doxorubicin—testicular cancer	0.00017	0.000564	CcSEcCtD
Octreotide—Pharyngitis—Doxorubicin—testicular cancer	0.000169	0.000563	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—KIT—testicular cancer	0.000169	0.00189	CbGpPWpGaD
Octreotide—Oedema peripheral—Doxorubicin—testicular cancer	0.000168	0.000559	CcSEcCtD
Octreotide—Asthenia—Etoposide—testicular cancer	0.000167	0.000558	CcSEcCtD
Octreotide—Immune system disorder—Epirubicin—testicular cancer	0.000166	0.000554	CcSEcCtD
Octreotide—Back pain—Methotrexate—testicular cancer	0.000166	0.000552	CcSEcCtD
Octreotide—Pruritus—Etoposide—testicular cancer	0.000165	0.00055	CcSEcCtD
Octreotide—Arrhythmia—Epirubicin—testicular cancer	0.000165	0.000548	CcSEcCtD
Octreotide—Visual impairment—Doxorubicin—testicular cancer	0.000164	0.000547	CcSEcCtD
Octreotide—Alopecia—Epirubicin—testicular cancer	0.000163	0.000542	CcSEcCtD
Octreotide—Vomiting—Cisplatin—testicular cancer	0.000162	0.000539	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—KIT—testicular cancer	0.000162	0.00181	CbGpPWpGaD
Octreotide—Vision blurred—Methotrexate—testicular cancer	0.000161	0.000538	CcSEcCtD
Octreotide—Mental disorder—Epirubicin—testicular cancer	0.000161	0.000537	CcSEcCtD
Octreotide—Rash—Cisplatin—testicular cancer	0.000161	0.000535	CcSEcCtD
Octreotide—Dermatitis—Cisplatin—testicular cancer	0.000161	0.000534	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—testicular cancer	0.00016	0.000534	CcSEcCtD
Octreotide—Erythema—Epirubicin—testicular cancer	0.00016	0.000534	CcSEcCtD
Octreotide—Diarrhoea—Etoposide—testicular cancer	0.00016	0.000532	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—testicular cancer	0.000159	0.000529	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—testicular cancer	0.000159	0.000529	CcSEcCtD
Octreotide—Anaemia—Methotrexate—testicular cancer	0.000158	0.000527	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—testicular cancer	0.000158	0.000527	CcSEcCtD
Octreotide—Flushing—Doxorubicin—testicular cancer	0.000158	0.000527	CcSEcCtD
Octreotide—Flatulence—Epirubicin—testicular cancer	0.000158	0.000526	CcSEcCtD
Octreotide—Tension—Epirubicin—testicular cancer	0.000157	0.000524	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—FGFR3—testicular cancer	0.000156	0.00175	CbGpPWpGaD
Octreotide—Nervousness—Epirubicin—testicular cancer	0.000156	0.000518	CcSEcCtD
Octreotide—Back pain—Epirubicin—testicular cancer	0.000155	0.000516	CcSEcCtD
Octreotide—Malaise—Methotrexate—testicular cancer	0.000154	0.000514	CcSEcCtD
Octreotide—Dizziness—Etoposide—testicular cancer	0.000154	0.000514	CcSEcCtD
Octreotide—Muscle spasms—Epirubicin—testicular cancer	0.000154	0.000513	CcSEcCtD
Octreotide—Immune system disorder—Doxorubicin—testicular cancer	0.000154	0.000512	CcSEcCtD
Octreotide—Vertigo—Methotrexate—testicular cancer	0.000154	0.000512	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—testicular cancer	0.000152	0.000507	CcSEcCtD
Octreotide—Nausea—Cisplatin—testicular cancer	0.000151	0.000504	CcSEcCtD
Octreotide—Vision blurred—Epirubicin—testicular cancer	0.000151	0.000503	CcSEcCtD
Octreotide—Alopecia—Doxorubicin—testicular cancer	0.000151	0.000501	CcSEcCtD
Octreotide—Cough—Methotrexate—testicular cancer	0.000149	0.000498	CcSEcCtD
Octreotide—Mental disorder—Doxorubicin—testicular cancer	0.000149	0.000497	CcSEcCtD
Octreotide—Ill-defined disorder—Epirubicin—testicular cancer	0.000149	0.000495	CcSEcCtD
Octreotide—Convulsion—Methotrexate—testicular cancer	0.000148	0.000494	CcSEcCtD
Octreotide—Vomiting—Etoposide—testicular cancer	0.000148	0.000494	CcSEcCtD
Octreotide—Erythema—Doxorubicin—testicular cancer	0.000148	0.000494	CcSEcCtD
Octreotide—Malnutrition—Doxorubicin—testicular cancer	0.000148	0.000494	CcSEcCtD
Octreotide—Anaemia—Epirubicin—testicular cancer	0.000148	0.000493	CcSEcCtD
Octreotide—Agitation—Epirubicin—testicular cancer	0.000147	0.00049	CcSEcCtD
Octreotide—Rash—Etoposide—testicular cancer	0.000147	0.00049	CcSEcCtD
Octreotide—Dermatitis—Etoposide—testicular cancer	0.000147	0.00049	CcSEcCtD
Octreotide—Headache—Etoposide—testicular cancer	0.000146	0.000487	CcSEcCtD
Octreotide—Flatulence—Doxorubicin—testicular cancer	0.000146	0.000487	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—testicular cancer	0.000146	0.000486	CcSEcCtD
Octreotide—Myalgia—Methotrexate—testicular cancer	0.000146	0.000486	CcSEcCtD
Octreotide—Chest pain—Methotrexate—testicular cancer	0.000146	0.000486	CcSEcCtD
Octreotide—Tension—Doxorubicin—testicular cancer	0.000146	0.000485	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000145	0.000482	CcSEcCtD
Octreotide—Malaise—Epirubicin—testicular cancer	0.000145	0.000481	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—FGFR3—testicular cancer	0.000144	0.00161	CbGpPWpGaD
Octreotide—Discomfort—Methotrexate—testicular cancer	0.000144	0.00048	CcSEcCtD
Octreotide—Nervousness—Doxorubicin—testicular cancer	0.000144	0.00048	CcSEcCtD
Octreotide—Vertigo—Epirubicin—testicular cancer	0.000144	0.00048	CcSEcCtD
Octreotide—Syncope—Epirubicin—testicular cancer	0.000144	0.000479	CcSEcCtD
Octreotide—Back pain—Doxorubicin—testicular cancer	0.000143	0.000478	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—KIT—testicular cancer	0.000143	0.0016	CbGpPWpGaD
Octreotide—Muscle spasms—Doxorubicin—testicular cancer	0.000143	0.000475	CcSEcCtD
Octreotide—Palpitations—Epirubicin—testicular cancer	0.000142	0.000472	CcSEcCtD
Octreotide—Loss of consciousness—Epirubicin—testicular cancer	0.000141	0.000469	CcSEcCtD
Octreotide—Cough—Epirubicin—testicular cancer	0.00014	0.000466	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—testicular cancer	0.00014	0.000465	CcSEcCtD
Octreotide—Vision blurred—Doxorubicin—testicular cancer	0.00014	0.000465	CcSEcCtD
Octreotide—Convulsion—Epirubicin—testicular cancer	0.000139	0.000462	CcSEcCtD
Octreotide—Infection—Methotrexate—testicular cancer	0.000139	0.000462	CcSEcCtD
Octreotide—Nausea—Etoposide—testicular cancer	0.000139	0.000462	CcSEcCtD
Octreotide—Hypertension—Epirubicin—testicular cancer	0.000138	0.000461	CcSEcCtD
Octreotide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000138	0.000458	CcSEcCtD
Octreotide—Nervous system disorder—Methotrexate—testicular cancer	0.000137	0.000456	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—testicular cancer	0.000137	0.000456	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—testicular cancer	0.000137	0.000456	CcSEcCtD
Octreotide—Arthralgia—Epirubicin—testicular cancer	0.000136	0.000454	CcSEcCtD
Octreotide—Myalgia—Epirubicin—testicular cancer	0.000136	0.000454	CcSEcCtD
Octreotide—Chest pain—Epirubicin—testicular cancer	0.000136	0.000454	CcSEcCtD
Octreotide—Agitation—Doxorubicin—testicular cancer	0.000136	0.000454	CcSEcCtD
Octreotide—Anxiety—Epirubicin—testicular cancer	0.000136	0.000453	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—testicular cancer	0.000136	0.000452	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000136	0.000451	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—testicular cancer	0.000135	0.00045	CcSEcCtD
Octreotide—Discomfort—Epirubicin—testicular cancer	0.000135	0.000449	CcSEcCtD
Octreotide—Malaise—Doxorubicin—testicular cancer	0.000134	0.000445	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—testicular cancer	0.000133	0.000444	CcSEcCtD
Octreotide—Vertigo—Doxorubicin—testicular cancer	0.000133	0.000444	CcSEcCtD
Octreotide—Anorexia—Methotrexate—testicular cancer	0.000133	0.000444	CcSEcCtD
Octreotide—Syncope—Doxorubicin—testicular cancer	0.000133	0.000443	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—KIT—testicular cancer	0.000132	0.00148	CbGpPWpGaD
Octreotide—Palpitations—Doxorubicin—testicular cancer	0.000131	0.000436	CcSEcCtD
Octreotide—Anaphylactic shock—Epirubicin—testicular cancer	0.000131	0.000436	CcSEcCtD
Octreotide—Oedema—Epirubicin—testicular cancer	0.000131	0.000436	CcSEcCtD
Octreotide—Loss of consciousness—Doxorubicin—testicular cancer	0.00013	0.000434	CcSEcCtD
Octreotide—Infection—Epirubicin—testicular cancer	0.00013	0.000433	CcSEcCtD
Octreotide—Cough—Doxorubicin—testicular cancer	0.000129	0.000431	CcSEcCtD
Octreotide—Shock—Epirubicin—testicular cancer	0.000129	0.000429	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—testicular cancer	0.000129	0.000428	CcSEcCtD
Octreotide—Nervous system disorder—Epirubicin—testicular cancer	0.000128	0.000427	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—testicular cancer	0.000128	0.000427	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—testicular cancer	0.000128	0.000426	CcSEcCtD
Octreotide—Tachycardia—Epirubicin—testicular cancer	0.000128	0.000425	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000127	0.000424	CcSEcCtD
Octreotide—Skin disorder—Epirubicin—testicular cancer	0.000127	0.000423	CcSEcCtD
Octreotide—Hyperhidrosis—Epirubicin—testicular cancer	0.000126	0.000421	CcSEcCtD
Octreotide—Insomnia—Methotrexate—testicular cancer	0.000126	0.000421	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—testicular cancer	0.000126	0.00042	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—testicular cancer	0.000126	0.00042	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—testicular cancer	0.000126	0.00042	CcSEcCtD
Octreotide—Anxiety—Doxorubicin—testicular cancer	0.000126	0.000419	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—testicular cancer	0.000126	0.000418	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000125	0.000418	CcSEcCtD
Octreotide—Discomfort—Doxorubicin—testicular cancer	0.000125	0.000415	CcSEcCtD
Octreotide—Anorexia—Epirubicin—testicular cancer	0.000125	0.000415	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—testicular cancer	0.000125	0.000415	CcSEcCtD
Octreotide—Somnolence—Methotrexate—testicular cancer	0.000124	0.000414	CcSEcCtD
Octreotide—Dry mouth—Doxorubicin—testicular cancer	0.000124	0.000411	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—testicular cancer	0.000123	0.00041	CcSEcCtD
Octreotide—Decreased appetite—Methotrexate—testicular cancer	0.000122	0.000405	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—testicular cancer	0.000121	0.000403	CcSEcCtD
Octreotide—Oedema—Doxorubicin—testicular cancer	0.000121	0.000403	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000121	0.000402	CcSEcCtD
Octreotide—Fatigue—Methotrexate—testicular cancer	0.000121	0.000401	CcSEcCtD
Octreotide—Infection—Doxorubicin—testicular cancer	0.00012	0.0004	CcSEcCtD
Octreotide—Pain—Methotrexate—testicular cancer	0.00012	0.000398	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000119	0.000397	CcSEcCtD
Octreotide—Shock—Doxorubicin—testicular cancer	0.000119	0.000397	CcSEcCtD
Octreotide—Nervous system disorder—Doxorubicin—testicular cancer	0.000119	0.000395	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000119	0.000395	CcSEcCtD
Octreotide—Insomnia—Epirubicin—testicular cancer	0.000118	0.000394	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—testicular cancer	0.000118	0.000393	CcSEcCtD
Octreotide—Skin disorder—Doxorubicin—testicular cancer	0.000118	0.000392	CcSEcCtD
Octreotide—Paraesthesia—Epirubicin—testicular cancer	0.000117	0.000391	CcSEcCtD
Octreotide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000117	0.00039	CcSEcCtD
Octreotide—Dyspnoea—Epirubicin—testicular cancer	0.000117	0.000388	CcSEcCtD
Octreotide—Somnolence—Epirubicin—testicular cancer	0.000116	0.000387	CcSEcCtD
Octreotide—Anorexia—Doxorubicin—testicular cancer	0.000115	0.000384	CcSEcCtD
Octreotide—Feeling abnormal—Methotrexate—testicular cancer	0.000115	0.000384	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—testicular cancer	0.000115	0.000383	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000114	0.000381	CcSEcCtD
Octreotide—Decreased appetite—Epirubicin—testicular cancer	0.000114	0.000379	CcSEcCtD
Octreotide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000113	0.000376	CcSEcCtD
Octreotide—Fatigue—Epirubicin—testicular cancer	0.000113	0.000376	CcSEcCtD
Octreotide—Pain—Epirubicin—testicular cancer	0.000112	0.000373	CcSEcCtD
Octreotide—Constipation—Epirubicin—testicular cancer	0.000112	0.000373	CcSEcCtD
Octreotide—Urticaria—Methotrexate—testicular cancer	0.000111	0.00037	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—testicular cancer	0.000111	0.000368	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—testicular cancer	0.000111	0.000368	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00011	0.000367	CcSEcCtD
Octreotide—Insomnia—Doxorubicin—testicular cancer	0.00011	0.000365	CcSEcCtD
Octreotide—Paraesthesia—Doxorubicin—testicular cancer	0.000109	0.000362	CcSEcCtD
Octreotide—Dyspnoea—Doxorubicin—testicular cancer	0.000108	0.000359	CcSEcCtD
Octreotide—Feeling abnormal—Epirubicin—testicular cancer	0.000108	0.000359	CcSEcCtD
Octreotide—Somnolence—Doxorubicin—testicular cancer	0.000108	0.000358	CcSEcCtD
Octreotide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000107	0.000356	CcSEcCtD
Octreotide—Dyspepsia—Doxorubicin—testicular cancer	0.000107	0.000355	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—testicular cancer	0.000105	0.00035	CcSEcCtD
Octreotide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000105	0.000348	CcSEcCtD
Octreotide—Fatigue—Doxorubicin—testicular cancer	0.000104	0.000347	CcSEcCtD
Octreotide—Urticaria—Epirubicin—testicular cancer	0.000104	0.000346	CcSEcCtD
Octreotide—Pain—Doxorubicin—testicular cancer	0.000104	0.000345	CcSEcCtD
Octreotide—Constipation—Doxorubicin—testicular cancer	0.000104	0.000345	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—testicular cancer	0.000103	0.000344	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—testicular cancer	0.000103	0.000344	CcSEcCtD
Octreotide—Hypersensitivity—Methotrexate—testicular cancer	0.000103	0.000343	CcSEcCtD
Octreotide—Asthenia—Methotrexate—testicular cancer	0.0001	0.000334	CcSEcCtD
Octreotide—Feeling abnormal—Doxorubicin—testicular cancer	9.98e-05	0.000332	CcSEcCtD
Octreotide—Gastrointestinal pain—Doxorubicin—testicular cancer	9.9e-05	0.00033	CcSEcCtD
Octreotide—Pruritus—Methotrexate—testicular cancer	9.89e-05	0.000329	CcSEcCtD
Octreotide—Hypersensitivity—Epirubicin—testicular cancer	9.64e-05	0.000321	CcSEcCtD
Octreotide—Urticaria—Doxorubicin—testicular cancer	9.62e-05	0.00032	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—testicular cancer	9.57e-05	0.000319	CcSEcCtD
Octreotide—Body temperature increased—Doxorubicin—testicular cancer	9.57e-05	0.000319	CcSEcCtD
Octreotide—Diarrhoea—Methotrexate—testicular cancer	9.57e-05	0.000318	CcSEcCtD
Octreotide—Asthenia—Epirubicin—testicular cancer	9.39e-05	0.000313	CcSEcCtD
Octreotide—Pruritus—Epirubicin—testicular cancer	9.26e-05	0.000308	CcSEcCtD
Octreotide—Dizziness—Methotrexate—testicular cancer	9.25e-05	0.000308	CcSEcCtD
Octreotide—Diarrhoea—Epirubicin—testicular cancer	8.95e-05	0.000298	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—testicular cancer	8.92e-05	0.000297	CcSEcCtD
Octreotide—Vomiting—Methotrexate—testicular cancer	8.89e-05	0.000296	CcSEcCtD
Octreotide—Rash—Methotrexate—testicular cancer	8.82e-05	0.000293	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—testicular cancer	8.81e-05	0.000293	CcSEcCtD
Octreotide—Headache—Methotrexate—testicular cancer	8.76e-05	0.000292	CcSEcCtD
Octreotide—Asthenia—Doxorubicin—testicular cancer	8.69e-05	0.000289	CcSEcCtD
Octreotide—Dizziness—Epirubicin—testicular cancer	8.65e-05	0.000288	CcSEcCtD
Octreotide—Pruritus—Doxorubicin—testicular cancer	8.57e-05	0.000285	CcSEcCtD
Octreotide—Vomiting—Epirubicin—testicular cancer	8.32e-05	0.000277	CcSEcCtD
Octreotide—Nausea—Methotrexate—testicular cancer	8.31e-05	0.000276	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—testicular cancer	8.28e-05	0.000276	CcSEcCtD
Octreotide—Rash—Epirubicin—testicular cancer	8.25e-05	0.000275	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—testicular cancer	8.24e-05	0.000274	CcSEcCtD
Octreotide—Headache—Epirubicin—testicular cancer	8.2e-05	0.000273	CcSEcCtD
Octreotide—Dizziness—Doxorubicin—testicular cancer	8.01e-05	0.000267	CcSEcCtD
Octreotide—Nausea—Epirubicin—testicular cancer	7.77e-05	0.000259	CcSEcCtD
Octreotide—Vomiting—Doxorubicin—testicular cancer	7.7e-05	0.000256	CcSEcCtD
Octreotide—Rash—Doxorubicin—testicular cancer	7.63e-05	0.000254	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—testicular cancer	7.63e-05	0.000254	CcSEcCtD
Octreotide—Headache—Doxorubicin—testicular cancer	7.58e-05	0.000253	CcSEcCtD
Octreotide—Nausea—Doxorubicin—testicular cancer	7.19e-05	0.000239	CcSEcCtD
